Enrico Martin

20 Chapter 1 16. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2016;14(6):758-786. 17. Wasa J, Nishida Y, Tsukushi S, et al. MRI features in the differentiation of malignant peripheral ner ve sheath tumors and neurofibromas. Am J Roentgenol . 2010;194(6):1568-1574. doi:10.2214/ AJR.09.2724 18. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet . 2007;15(2):131-138. doi:10.1038/ sj.ejhg.5201676 LK - http://sfx.library. uu.nl/utrecht?sid=EMBASE&issn=101 84813&id=doi:10.1038%2Fsj.ejhg. 5201676&atitle=Neurofibromatosis+1& stitle=Eur.+J.+Hum.+Genet.&title=Europea n+Journal+of+Human+Genetics& volume=15&issue=2&spage=131& epage=138&aulast=Ferner&aufirst= Rosalie+E.&auinit=R.E.&aufull=Ferner +R.E.&coden=EJHGE&isbn=&pages=131- 19. Derlin T, Tornquist K, Munster S, et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med . 2013;38(1):e19-25. doi:10.1097/RLU.0b013e318266ce84 20. Reinert CP, Schuhmann MU, Bender B, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging . 2019;46(3):776-787. doi:10.1007/s00259- 018-4227-5 21. Perez-Roman RJ, Shelby Burks S, Debs L, Cajigas I, Levi AD. The Risk of Peripheral Nerve Tumor Biopsy in Suspected Benign Etiologies. Neurosurgery . January 2020. doi:10.1093/neuros/nyz549 22. Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Skeletal Radiol . August 2019. doi:10.1007/s00256-019-03290-1 23. Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol . 2014;4:324. doi:10.3389/fonc.2014.00324 24. Bradford D, Kim A. Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options Oncol . 2015;16(3):328. doi:10.1007/s11864-015- 0328-6 25. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet (London, England) . 2002;359(9325):2235-2241. doi:10.1016/S0140-6736(02)09292-9 26. Haas RL, Gronchi A, van de Sande MAJ, et al. Perioperative Management of Extremity Soft Tissue Sarcomas. J Clin Oncol . 2018;36(2):118-124. doi:10.1200/ JCO.2017.74.7527 27. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus s tandard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol . 2017;18(6):812-822. doi:10.1016/S1470-2045(17)30334-0 28. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma . 2017;2017:8685638. doi:10.1155/2017/8685638 29. Castellsagué J, Gel B, Fernández-Rodríguez J, et al. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med . 2015;7(5):608- 627. doi:10.15252/emmm.201404430 30. Torres KE, Zhu Q-S, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res . 2011;17(12):3943-3955. doi:10.1158/1078-0432.CCR-11-0193